{"id":"formoterol-oxis-turbuhaler","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Nervousness"},{"rate":"1-5","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. The drug has a rapid onset and long duration of action (12 hours), making it suitable for maintenance therapy in obstructive airway diseases. It also has anti-inflammatory properties through effects on mast cells and other immune cells in the airways.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:21.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT05202262","phase":"PHASE3","title":"A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-01-12","conditions":"Asthma","enrollment":645},{"nctId":"NCT05553184","phase":"NA","title":"Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2022-07-05","conditions":"Type 2 Diabetes, Obesity","enrollment":12},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT03691961","phase":"NA","title":"Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair)","status":"UNKNOWN","sponsor":"Hopital Foch","startDate":"2018-09-20","conditions":"Asthma","enrollment":24},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT03197818","phase":"PHASE3","title":"Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-14","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":990},{"nctId":"NCT02497001","phase":"PHASE3","title":"A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-08-10","conditions":"COPD","enrollment":1902},{"nctId":"NCT01787097","phase":"PHASE4","title":"Effect of Symbicort ® on GR in Sputum in COPD","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"Chronic Obstructive Lung Disease","enrollment":31},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT03262012","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-08-09","conditions":"COPD","enrollment":416},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT02233803","phase":"PHASE4","title":"A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-14","conditions":"Asthma","enrollment":239},{"nctId":"NCT01397890","phase":"PHASE4","title":"Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":793},{"nctId":"NCT00624754","phase":"PHASE2","title":"Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-03","conditions":"Obstructive Airway Disease","enrollment":32},{"nctId":"NCT01836016","phase":"PHASE3","title":"A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2013-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":360},{"nctId":"NCT01047553","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":251},{"nctId":"NCT00839800","phase":"PHASE3","title":"Study to Investigate the Efficacy of Symbicort® SMART.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Asthma","enrollment":2091},{"nctId":"NCT00496470","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":660},{"nctId":"NCT01048333","phase":"PHASE2","title":"Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":109},{"nctId":"NCT01069289","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1293},{"nctId":"NCT00628862","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":613},{"nctId":"NCT01257048","phase":"EARLY_PHASE1","title":"Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation","enrollment":34},{"nctId":"NCT00542880","phase":"PHASE4","title":"Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":442},{"nctId":"NCT00489853","phase":"PHASE4","title":"Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":137},{"nctId":"NCT00837967","phase":"PHASE3","title":"Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-01","conditions":"Asthma","enrollment":25},{"nctId":"NCT00536731","phase":"PHASE3","title":"Symbicort Rapihaler Therapeutic Equivalence Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Bronchial Asthma","enrollment":742},{"nctId":"NCT00989833","phase":"PHASE2","title":"Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Exercise Induced Asthma","enrollment":66},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":430},{"nctId":"NCT00837629","phase":"","title":"Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT00242775","phase":"PHASE3","title":"Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":2100},{"nctId":"NCT00252785","phase":"PHASE3","title":"Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Asthma","enrollment":340},{"nctId":"NCT00244608","phase":"PHASE3","title":"A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-05","conditions":"Asthma","enrollment":100},{"nctId":"NCT00259779","phase":"PHASE3","title":"Comparison Between Symbicort® and Prednisolone in COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":120},{"nctId":"NCT00252824","phase":"PHASE3","title":"STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00326053","phase":"PHASE3","title":"Prevention of Asthma Relapse After Discharge From Emergency","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-05","conditions":"Asthma","enrollment":600},{"nctId":"NCT00242411","phase":"PHASE4","title":"MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1900},{"nctId":"NCT00288379","phase":"PHASE3","title":"SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-10","conditions":"Asthma","enrollment":16},{"nctId":"NCT00255255","phase":"PHASE3","title":"Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-11","conditions":"Asthma","enrollment":120},{"nctId":"NCT00419744","phase":"PHASE3","title":"A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1200},{"nctId":"NCT00206154","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1500},{"nctId":"NCT00421122","phase":"PHASE3","title":"Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":315},{"nctId":"NCT00206167","phase":"PHASE3","title":"A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1600},{"nctId":"NCT00238784","phase":"PHASE3","title":"SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Asthma","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group B patients: Formoterol (Oxis Turbuhaler®).","Oxis Turbuhaler"],"phase":"phase_3","status":"active","brandName":"Formoterol (Oxis Turbuhaler®)","genericName":"Formoterol (Oxis Turbuhaler®)","companyName":"Henan University of Traditional Chinese Medicine","companyId":"henan-university-of-traditional-chinese-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}